Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsRisk of hyperkalaemiaReduced ejection fractionSevere hyperkalaemiaMild hyperkalaemiaDAPA-HFHazard ratioEjection fractionHeart failureMRA useSodium-glucose cotransporter 2 inhibitor dapagliflozinDAPA-HF studyHeart Failure TrialCox regression analysisLife-saving therapyInhibitor dapagliflozinFailure TrialAdverse outcomesReceptor antagonistHyperkalaemiaPatientsDapagliflozinTreatment assignmentHFrEFPlacebo